captomize limited glp 1 GLP-1 Weight Loss Treatment Online shoppers warned of 'dangerous'

10.1534/genetics.119.302939 [DOI] [PMC free article] [PubMed] [Google Scholar] Izadi A., Ebrahimi S., Shirazi S., Taghizadeh S., Parizad M., Farzadi L., et al

Agarwal, A., et al

The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects

JAMA (2022) 327:53445

Lillys Zepbound, approved in November 2023 as the Indiana-based drug giants answer to Novo Nordisks Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase 3 trial, and a mid-stage study of another Lilly experimental medicine, called retatrutide, showed 24% weight loss after just 48 weeks

Once mixed correctly, the solution can be measured accurately using a suitable syringe